Cloridarol 

Cloridarol is a human islet amyloid peptide (hIAPP) inhibitor that prevents its abnormal misfolding and aggregation. Cloridarol can increase cell viability, inhibit apoptosis, and protect islet β-cells from hIAPP-induced cell toxicity. Cloridarol can be used for the research of type 2 diabetes (T2D)^[1].

Cloridarol (25-125 µM; 0-20 h) inhibits hIAPP aggregation in a dose-dependent manner, reducing final fibril formation by up to 55.6%^[1].
Cloridarol (125 µM; 5-24 h) modifies hIAPP aggregate morphology and inhibits its secondary structure transition to β-sheet, maintaining random coil structure^[1].
Cloridarol (125 µM; 0-25 h) inhibits hIAPP aggregation from lag and early growth phase seeds but not from equilibrium phase fibrils^[1].
Cloridarol (25-125 µM; 24-48 h) protects RIN-m5F cells from hIAPP-induced toxicity, as evidenced by an increase in cell viability and a decrease in apoptosis^[1].
Cloridarol (50 µM; 0-900 min) reduces hIAPP-induced membrane leakage in large unilamellar vesicle (LUV)s, contributing to its protective effect against hIAPP toxicity^[1].
Cloridarol binds to the C-terminal β-sheet region of the hIAPP pentamer, disturbing its structure and reducing β-sheet content to inhibit aggregation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

258.70

C₁₅H₁₁ClO₂

3611-72-1

ClC1=CC=C(C=C1)C(O)C=2OC=3C=CC=CC3C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tang Y, et al. Repurposing a Cardiovascular Disease Drug of Cloridarol as hIAPP Inhibitor. ACS Chem Neurosci. 2021;12(8):1419-1427.  [Content Brief]